FibroBiologics Files 8-K: Material Agreement, Equity Sales

TL;DR

FibroBiologics just dropped an 8-K: material agreement signed, equity sold. Watch this space.

AI Summary

FibroBiologics, Inc. filed an 8-K on December 15, 2025, reporting on events that occurred on December 14, 2025. The filing indicates a material definitive agreement, unregistered sales of equity securities, and a Regulation FD disclosure. The company, incorporated in Delaware with its principal executive offices in Houston, Texas, operates in the Pharmaceutical Preparations industry.

Why It Matters

This 8-K filing signals significant corporate activity for FibroBiologics, Inc., including a new material agreement and the sale of equity, which could impact its financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves unregistered sales of equity securities, which can sometimes indicate financial strain or dilutive financing activities.

Key Numbers

• 001-41934 — SEC File Number (Identifies the company's filing with the SEC.)
• 86-3329066 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• FibroBiologics, Inc. (company) — Registrant
• December 14, 2025 (date) — Earliest event reported
• December 15, 2025 (date) — Date of report
• 455 E. Medical Center Blvd, Suite 300, Houston, Texas 77598 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value FBLG The Nasdaq Stock Mar
• $0.33 — re in the Registered Direct Offering is $0.33 (the "Offering Price"). Additionally,
• $1.7 m — erings are expected to be approximately $1.7 million, before deducting placement agent
• $1.7 million — itional gross proceeds of approximately $1.7 million. However, the Company cannot predict wh
• $25,000 — ement Agent non-accountable expenses of $25,000 and clearing fees of $15,950. Additiona
• $15,950 — xpenses of $25,000 and clearing fees of $15,950. Additionally, the Company will issue t
• $0.4125 — Common Stock), at an exercise price of $0.4125 per share (the "Placement Agent Warrant

Filing Documents

• fblg-20251214.htm (8-K) — 70KB
• fblg-ex4_1.htm (EX-4.1) — 160KB
• fblg-ex4_2.htm (EX-4.2) — 160KB
• fblg-ex5_1.htm (EX-5.1) — 14KB
• fblg-ex10_1.htm (EX-10.1) — 402KB
• fblg-ex10_2.htm (EX-10.2) — 12KB
• fblg-ex99_1.htm (EX-99.1) — 20KB
• img111178190_0.jpg (GRAPHIC) — 24KB
• img111178190_1.gif (GRAPHIC) — 0KB
• img226614769_0.jpg (GRAPHIC) — 8KB
• 0001193125-25-319441.txt ( ) — 1122KB
• fblg-20251214.xsd (EX-101.SCH) — 24KB
• fblg-20251214_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On December 14, 2025, FibroBiologics, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional investors (the "Purchasers"), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the "Registered Direct Offering"), 5,227,275 shares (the "Shares") of the Company's common stock, $0.00001 par value per share (the "Common Stock"). The price of each Share in the Registered Direct Offering is $0.33 (the "Offering Price"). Additionally, pursuant to the Purchase Agreement, the Company will issue to the Purchasers, in a concurrent private placement, warrants to purchase one share of its Common Stock for each Share of Common Stock purchased in the Registered Direct Offering for an aggregate of 5,227,275 shares of Common Stock (the "Warrants"). The exercisability of the Warrants is subject to stockholder approval as described below. The exercise price of the Warrants is $0.33 per share. The gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses payable by the Company. In addition, if the holders of the unregistered Warrants exercise such Warrants in full for cash following stockholder approval, the Company would receive additional gross proceeds of approximately $1.7 million. However, the Company cannot predict when or if the Warrants will be exercised for cash or exercised at all. It is possible that the Warrants may be exercised on a cashless (net) basis as described below or may expire and never be exercised. The Registered Direct Offering and concurrent private placement are expected to close on or about December 16, 2025, subject to the satisfaction of customary closing conditions. The Company currently plans to use the net proceeds from the Registered Direct Offering and concurrent private plac

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The disclosure set forth above in Item 1.01 of this Form 8-K relating to (i) the issuance of the Warrants to the Purchasers pursuant to the Purchase Agreement, including the Warrant Shares to be issued in connection with exercises of the Warrants, and (ii) the issuance of the Placement Agent Warrants to the Placement Agent (or its designees) pursuant to the Engagement Letter, including the shares of Common Stock to be issued in connection with exercises of the Placement Agent Warrants, is incorporated by reference herein in its entirety. The maximum number of shares of Common Stock of the Company that may be issued through the exercise of the Warrants is 5,227,275 shares, subject to customary anti-dilution adjustments. The maximum number of shares of Common Stock of the Company that may be issued through the exercise of the Placement Agent Warrants is 365,909 shares, subject to customary anti-dilution adjustments. The offer and sale of the Warrants and the Warrant Shares to be issued in connection with exercises of the Warrants pursuant to the Purchase Agreement and the offer and sale of the Placement Agent Warrants and the shares of Common Stock to be issued in connection with exercises of the Placement Agent Warrants pursuant to the Engagement Letter was and will be made in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. This Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. The Company issued a press release announcing the Registered Direct Offering and concurrent private placement on December 15, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not incorporated by reference into any of the Company's filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 4.1 Form of Warrant 4.2 Form of Placement Agent Warrant 5.1 Opinion of Sichenzia Ross Ference Carmel LLP 10.1 Form of Securities Purchase Agreement, dated December 14, 2025, between FibroBiologics, Inc. and the purchasers named therein 10.2 Form of Voting Agreement 23.1 Consent of Sichenzia Ross Ference Carmel LLP (contained in Exhibit 5.1) 99.1 Press Release dated December 15, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FibroBiologics, Inc. Date: December 15, 2025 By: /s/ Peter O'Heeron Peter O'Heeron Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR